MetaCap

City Therapeutics (CTY) vs Omeros (OMER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

City Therapeutics is the larger company by market cap ($1.03 billion vs $983.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTY-13.75%OMER-18.46%
+19%-5%-29%
Oct 16, 20261 yearNov 20, 2026
CTY-13.75%OMER-18.46%
+15%-3%-21%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTY versus OMER key metrics
MetricCTYOMER
Share price$19.32$13.21
Market cap$1.03B$983.66M
1-day change+5.29%-5.71%
YTD return—-23.11%
1-year return—+48.93%
5-year return—+77.79%
P/E ratio (TTM)—15.92
Forward P/E—11.95
EPS (TTM)$-2.53$0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-3.35M
52-week high$23.88$21.24
52-week low$15.81$6.70
Distance from 52-week high-19.10%-37.81%
Analyst consensusstrong_buybuy
Avg. price target upside+93.22%+108.18%
Average volume328.87K1.36M
Shares outstanding53.39M74.46M
Employees75175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About City Therapeutics

CTY stock →

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

CTY vs OMER FAQ

Which is bigger, City Therapeutics or Omeros?

City Therapeutics (CTY) is larger, with a market capitalization of $1.03B compared with $983.66M for Omeros (OMER).

Are City Therapeutics and Omeros in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons